Amitabh Gulati, MD
Pain Medicine · New York, NYNPI 1285855486
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $383,141 of the $614,406 with a category attached, or 62.4%. 32 manufacturers reported payments, led by SPR Therapeutics, Inc at 54.5% of the total. Reporting peaked in 2022 at $167,261 and has fallen 64.6% since, to $59,159 in 2025. Among pain medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 694 payments — averaging $885.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SPR Therapeutics, Inc$335K
- Medtronic$169K
- Nalu Medical, Inc.$38K
- Hinge Health, Inc.$34K
- Rivanna Medical, Inc$11K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$8K
- plus $20K from 26 others
Across 1 payment — averaging $12,600 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rivanna Medical, Inc$13K
What the payments were for
- Consulting fees$383,14162%
- Speaking & faculty fees$120,38820%
- Grants$3,9471%
- Travel & lodging$57,7899%
- Food & beverage$47,6688%
- Gifts$3920%
- Entertainment$1,0830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SPR Therapeutics, Inc | 234 | $335,109 |
| Medtronic(2 entities) | 322 | $169,271 |
| Nalu Medical, Inc. | 39 | $37,896 |
| Hinge Health, Inc. | 8 | $34,042 |
| Rivanna Medical, Inc | 5 | $10,655 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $7,622 |
| Pacira Pharmaceuticals Incorporated | 2 | $6,750 |
| Tersera Therapeutics LLC | 6 | $4,362 |
| Stratus Medical, LLC | 32 | $2,446 |
| GRT US Holding, Inc. | 3 | $1,898 |
| Eisai Inc. | 1 | $1,080 |
| Flowonix Medical Incorporated | 1 | $889 |
| Abbott | 8 | $431 |
| Biotronik NRO, Inc. | 4 | $421 |
| Painteq LLC | 1 | $259 |
| Averitas Pharma Inc. | 1 | $166 |
| Bioness Inc | 1 | $153 |
| Stimwave Technologies Incorporated | 2 | $143 |
| MML US, Inc. | 1 | $129 |
| AbbVie | 5 | $91 |
| Si-bone, Inc. | 2 | $89 |
| Vertiflex, Inc. | 1 | $82 |
| Tonix Medicines, Inc. | 1 | $77 |
| Boston Scientific | 1 | $70 |
| Heron Therapeutics, Inc. | 1 | $69 |
| Vertex | 1 | $53 |
| Foundation Fusion Solutions, LLC | 1 | $40 |
| Angiodynamics, Inc. | 1 | $29 |
| Johnson & Johnson | 1 | $23 |
| Saluda Medical Americas, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Nevro Corp. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRINT PNS System$329,961
- SYNCHROMEDII$57,408
- INTELLIS ADAPTIVESTIM$44,177
- Nalu Neurostimulation System$37,499
- Enso$33,650
- SYNCHROMED$14,409
- Accuro$10,632
- EXPAREL$6,750
- SYNCRA CRT-P$5,132
- PRIALT$4,284
- INTELLIS$4,124
- XIFAXAN$3,740
- KYPHON Balloon Kyphoplasty$3,000
- RELISTOR$2,293
- VANTA ADAPTIVESTIM$2,070
- Qutenza$2,039
- LUCEMYRA$1,500
- LIORESAL$1,500
- Nimbus$1,255
- Prometra II$889
How this compares
$614,406 in reported general payments places this provider in the 95th percentile of 503 pain medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucyntaTapentadol Hcl | 35 | $53,235 |
| OxycontinOxycodone Hcl | 45 | $39,627 |
| Xtampza ErOxycodone Myristate | 21 | $29,739 |
| Fentanyl | 80 | $13,337 |
| LyricaPregabalin | 12 | $10,319 |
| Hydromorphone ErHydromorphone Hcl | 35 | $9,630 |
| Oxycodone Hcl | 300 | $8,275 |
| Lidocaine | 69 | $6,690 |
| Oxymorphone Hcl ErOxymorphone Hcl | 11 | $6,319 |
| Buprenorphine | 12 | $4,275 |
| Gabapentin | 224 | $3,579 |
| Pregabalin | 161 | $3,533 |
| Hydromorphone Hcl | 114 | $2,508 |
| Naloxone Hcl | 30 | $1,852 |
| Morphine Sulfate | 58 | $1,778 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in New York
- David SpinnerNew York$391K
- Eric LeeNew York$117K
- Christopher GhariboNew York$91K
- Randa JaafarNew York$87K
- Boris LeybelNew York$58K
- Chirag ShahNew York$48K
- Annie Layno-MosesNew York$29K
- Raj MurthyNew York$24K
- David CassagnolNew York$22K
- Scott MaddaloNew York$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.